9 September 2026

Osteopore secures market access to Thailand orthopaedic bone reconstruction market

Highlights

- **Osteopore has secured market access in Thailand for the full range of its orthopaedic products.**
- **The Thai orthopaedic devices market was valued at USD 749 million in 2025 and projected to reach USD 1.5 billion by 2033[1] at a compound annual growth rate of 9.2% — among the fastest in the Asia-Pacific region.**
- **Osteopore has also secured its supply chain and logistics network into Thailand through a partnership with DCH Auriga (Auriga), an Asia-based integrated market management provider specialising in healthcare.**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that it has secured market access in Thailand for the full range of its orthopaedic products, which includes the flagship product for medial opening wedge high tibial osteotomy procedures.

Osteopore has also secured its supply chain and logistics network into Thailand through a partnership with Auriga, an Asia-based integrated market management provider specialising in healthcare.

[1] Datacube Research, Thailand Orthopedic Devices Market, 2025.

As part of the arrangement, Auriga will be Osteopore's market authorisation holder and import Osteopore's regenerative devices into Thailand and supply to hospitals and clinics as directed by Osteopore.

Thailand represents a substantial and fast-growing market for Osteopore's bone regeneration technology. The Thailand orthopaedic devices market was valued at approximately USD 749 million in 2025 and is projected to reach approximately USD 1.5 billion by 2033, reflecting a compound annual growth rate of 9.2% — among the fastest in the Asia-Pacific region[1].

Bone-repair orthobiologics and bone graft substitutes — a segment which Osteopore's orthopaedic regenerative scaffolds addresses — typically represents approximately 8 to 10% of theorthopaedic devices market by value; on that basis, the Company estimates the addressable segment in Thailand at approximately USD 60 to 80 million annually.

This segment is propelled by expanding access to reconstructive procedures under Thailand's universal healthcare coverage, a rising orthopaedic disease burden, and one of the world's highest road-trauma rates, generating sustained demand for materials that reconstruct bone defects arising from high-energy fractures.

The next step for Osteopore is to proceed with product listing in target public and private hospitals in Bangkok.

Commenting on obtaining market access to Thailand, CEO Dr Yujing Lim, said:
"Our team has evaluated the potential of regional markets and Thailand has been identified as one of our key markets in ASEAN. I am glad to see that the team is smoothly executing on our regional expansion plans.

"We have also had the opportunity to share more about our regenerative devices in various meetings and conferences, and are looking forward to formal engagements", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About DCH Auriga

Auriga is an Asian-based integrated market management provider specialising in healthcare. We aim to connect the world's leading healthcare and life sciences companies to care providers and patients across Asia with a comprehensive range of responsible and effective market management solutions.

For over 50 years, we've helped our partners bring essential pharmaceutical and life science offerings to Asia with ethical integrity, partnership and transparency. Offering both commercial and logistics solutions, Auriga has operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam and the Philippines. In alignment with our mission to enrich lives with quality care, we distribute more than 500 brands at over 10,000 points of sale.

In November 2017, LF Asia was rebranded as DCH Auriga to signify a new chapter for the company with an exclusive focus on the healthcare industry. Our name is inspired by a constellation known in both the Western and Eastern traditions as 'the charioteer. It symbolises our commitment to help our principals navigate market complexities as they explore new opportunities. Auriga represents our mission of stewardship, expansion and growth.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.